Results of 2011 Annual General Meeting

RNS Number : 2998O

ReNeuron Group plc

15 September 2011

 



For Immediate Release

15 September 2011

ReNeuron

 

Results of 2011 Annual General Meeting

Guildford, UK, 15 September 2011: ReNeuron Group plc (LSE: RENE) announces that all resolutions put to its shareholders at today's 2011 Annual General Meeting were passed.

- End -

Enquiries:

Michael Hunt, Chief Executive Officer - ReNeuron            [phone]

Dr John Sinden, Chief Scientific Officer - ReNeuron

Lisa Baderoon, Mark Court, Isabel Podda                              [phone]

Buchanan Communications                                                         

Antony Legge, Oliver Rigby                                                          [phone]

Daniel Stewart & Company plc                                 

About ReNeuron

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development.  The Company is also developing stem cell therapies for other conditions such as peripheral arterial disease, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell^®products for use in academic and commercial research.  The Company's ReNcell^®CX and ReNcell^®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

 

END

 

 

RAGGCGDCSSBBGBU